Real‐World Survival Outcomes in EGFR‐Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single‐Center Clinical Data Warehouse Analysis in South Korea

Documenti analoghi

• Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy
  di: Junipearl Cheng, et al.
  Pubblicazione: (2025)
• The Effectiveness of Afatinib as First‐Line Treatment in Vietnamese Patients With EGFR‐Mutant Non–Small Cell Lung Cancer and Brain Metastases
  di: Thai Van Pham, et al.
  Pubblicazione: (2024)
• Real‐World Outcomes of Patients Treated With Gemcitabine Using Standardized Dose and Rate and Docetaxel for Advanced Soft Tissue Sarcoma in an Australian Sarcoma Center
  di: Isabella Wilson, et al.
  Pubblicazione: (2024)
• Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network
  di: Amy E. Smith, et al.
  Pubblicazione: (2025)
• Metastatic Lobular Breast Cancer: Outcomes of Patients Treated at a Single Tertiary Institution
  di: Ek Leone Oh, et al.
  Pubblicazione: (2025)